Tan Y et al. retrospectively analyzed the outcomes of 12 pediatric patients with low (< 20/μL blasts in the CSF) or high (blasts in CSF or significant intracranial mass) disease-burden CNS B-ALL treated with CD19 CAR-T cells. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.